title: Antiretroviral therapy and TB.
abstract: With the expansion and convergence of the HIV and TB epidemics worldwide, clinicians will increasingly will be called to manage and treat co-infected patients. TB and HIV medications have overlapping and additive toxicities that can complicate therapy. Additional clinical challenges include choice of optimal first and second line antiretroviral therapy, appropriate timing of antiretroviral initiation, management of immune reconstitution disease, and TB diagnosed after initiation of HIV therapy. Despite the complexities presented by co-infection, many programmes have integrated care and are successfully treating patients with both HIV and TB.
authors.affiliation: Division of HIV/AIDS, Tuberculosis Research Centre, Chennai, India.
authors.forename: Soumya
authors.initials: S
authors.lastname: Swaminathan
authors.forename: Annie
authors.initials: A
authors.lastname: Luetkemeyer
authors.forename: Padmini
authors.initials: P
authors.lastname: Srikantiah
authors.forename: Royce
authors.initials: R
authors.lastname: Lin
authors.forename: Edwin
authors.initials: E
authors.lastname: Charlebois
authors.forename: Diane V
authors.initials: DV
authors.lastname: Havlir
mesh_terms: D019380:Anti-HIV Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D007109:Immunity / Q000187:drug effects; D014376:Tuberculosis / Q000150:complications* / Q000188:drug therapy / Q000276:immunology
chemical_list: D019380:Anti-HIV Agents; D000995:Antitubercular Agents